Orchestra BioMed Holdings, Inc.OBIONASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank60
3Y CAGR-20.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-20.0%/yr
Annual compound
Percentile
P60
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 35.93% |
| 2024 | 26.56% |
| 2023 | 54.12% |
| 2022 | 70.25% |
| 2021 | -4.36% |
| 2020 | 0.00% |